<DOC>
	<DOC>NCT00591188</DOC>
	<brief_summary>The aim of this study is to determine preliminary efficacy of capecitabine and interferon-alpha in second-line after interleukin-2 based regimens in patients with MRCC</brief_summary>
	<brief_title>Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Histologically or cytologically confirmed renal carcinoma CTconfirmed metastatic sites Must have measurable disease, defined as ≥ 1 unidimensionally measurable lesion measured as ≥ 20 mm with conventional techniques OR as ≥ 10 mm with spiral CT scan Disease progression after IL2 Age 18 or older ECOG performance status 13 Life expectancy ≥ 2 months WBC ≥ 3,000/mm3 Platelet count ≥ 100,000/mm3 Hemoglobin ≥ 7.5 g/dL Creatinine ≤ 1.5 mg/dL (2.0 mg/dL in postnephrectomy patients) Total bilirubin ≤ 1.5 mg/dL AST ≤ 3.0 times normal Alkaline phosphatase ≤ 2.5 times normal (10 times ULN in presence of bone metastases) Not pregnant or nursing No history of autoimmune No history of serious cardiac arrhythmia, congestive heart failure, angina pectoris, or other severe cardiovascular disease (i.e., New York Heart Association class III or IV) No CNS metastases by neurologic exam and/or MRI No history of seizure disorders No local and/or systemic infections requiring antibiotics within 28 days prior to study entry No other malignancy Written informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>kidney cancer, capecitabine, interferon</keyword>
</DOC>